ArticleAmerican journal of translational research2023
Scutellarin inhibits glioma cell proliferation by up-regulating miR-15a expression.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells.Oncotarget · 2025Article
- Current advances on the therapeutic potential of scutellarin: an updated review.Natural products and bioprospecting · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of scutellarin on the proliferation of glioma cells through microRNA (miR)-15a.
methodsHuman glioma cell line T98G was cultured in vitro and divided into control group (without treatment), scutellarin group (with 10, 20, 40, 80, 160 μg/mL scutellarin, respectively), miR-15a negative control group (transfected with negative control-miR-15a + 80 μg/mL scutellarin) and miR-15a inhibitor group (transfected with miR-15a siRNA + 80 μg/mL scutellarin). The proliferation of T98G cells was detected by cell counting kit-8 (CCK-8), and the expression of miR-15a in T98G cells was detected by real-time fluorescence quantitative PCR (qRT-PCR). The apoptosis of T98G cells was assessed by flow cytometry, and the invasion of T98G cells was compared by Transwell method. The levels of proliferating cell nuclear antigen (PCNA), Bcl-2 related X protein (Bax) and matrix metalloproteinase 9 (MMP-9) in T98G cells were detected by Western blot (WB).
resultsCompared with that in the control group, the OD value of T98G cells in scutellarin group was significantly lower (P<0.05), with the increase of scutellarin concentration, the OD value of T98G cells decreased in turn, and 80 μg/mL was used as the optimal concentration of scutellarin to treat T98G cells for subsequent experiments. Compared with those in the control group, the miR-15a expression, apoptosis rate and Bax protein expression in T98G cells of scutellarin group were higher (P<0.05), and the OD value, number of invasive cells, PCNA and MMP-9 protein levels were lower (P<0.05). Compared with scutellarin group and miR-15a negative control group, the miR-15a expression, apoptosis rate and Bax protein expression in T98G cells of miR-15a inhibitor group were lower (P<0.05), and the OD value, number of invasive cells, PCNA and MMP-9 protein levels were higher (P<0.05).
conclusionsScutellarin can inhibit the proliferation, invasion and induce the apoptosis of glioma cells, which may be mediated by up-regulating the expression of miR-15a.
Indexed as
Identifiers
37056818PMC10086908W4365478867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.